In this interview with @NewsMedical, Head of Therapeutics Development Charles Wells discusses our current research into #tuberculosis, @WHO's new guidelines for TB care, and what inspired his career. Read more: https://bit.ly/3BJmYVt
👩💻📊Towards a more sustainable use of #AMR data: @IHIEurope project @FAIRplus_eu investigated in a case study the 'FAIRification' of @AMR_Combine data #StrongerTogether in the fight against #AMR and resistant #TB: https://twitter.com/FAIRplus_eu/status/1555154114924929025?s=20&t=trfEnNpti6-oxLFNz6xa6g
Though tremendous progress against TB has been made in the last two decades, the world needs new interventions to prevent and treat this disease. At the Gates MRI, we're supporting and developing multiple vaccines and therapeutics urgently needed to improve outcomes and #endTB. https://twitter.com/TBAlliance/status/1546529505317212163
"The biopharmaceutical industry agrees that we must use antibiotics judiciously, but those efforts are useless without a pipeline of novel antimicrobial treatments." #AMR https://www.washingtonpost.com/opinions/2022/07/29/superbugs-require-super-solutions/
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989.
The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non profit organisation, Bill & Melinda Gates Foundation and University of Dundee.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.